Plasminogen Activator Inhibitor-1 and Vascular Disease in Diabetes Mellitus

  • Douglas E. Vaughan
Part of the Contemporary Cardiology book series (CONCARD)


Atherosclerosis is a major cause of morbidity and mortality in patients with both insulindependent (IDDM) and non-insulin-dependent (NIDDM) diabetes mellitus. The impact of vascular disease on patients with diabetes is staggering, accounting for nearly 80% of deaths and more than 70% of hospitalizations.


Plasminogen Activator Plasminogen Activator Inhibitor Fibrinolytic Activity Fibrinolytic System Bovine Aortic Endothelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381–387.PubMedGoogle Scholar
  2. 2.
    van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984;259:14,914–14,921.Google Scholar
  3. 3.
    Pannekoek H, Veerman H, Lambers H, Diegaarde P, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986;5:2539–2544.PubMedGoogle Scholar
  4. 4.
    WimanB,ChmielewskaJ,RanbyM.Inactivationoftissueplasminogenactivatorinplasma.Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984;259:3644–3647.Google Scholar
  5. 5.
    Andreasen PA, Nielsen LS, Kristensen P, Grondahl-Hansen J, et al. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986;261:7644–7651.PubMedGoogle Scholar
  6. 6.
    Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, et al. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1990;87:3530–3533.PubMedCrossRefGoogle Scholar
  7. 7.
    Vaughan DE, Rouleau J-L, Arnold JMO, Menapace FJ, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442–447.PubMedCrossRefGoogle Scholar
  8. 8.
    LoskutoffDJ,SamadF.Theadipocyteandhemostaticbalanceinobesity:studiesofPAl-1.Arterioscler Thromb Vasc Biol 1998;18:1–6.Google Scholar
  9. 9.
    Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984;74:1465–1472.PubMedCrossRefGoogle Scholar
  10. 10.
    Vaughan DE, Declerck PJ, VanHoutte E, et al. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ Res 1990;67:1281–1286.PubMedCrossRefGoogle Scholar
  11. 11.
    Andreasen PA, Sottrup-Jensen L, Kjoller L, Nykjaer A, et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 1994;338:239–245.PubMedCrossRefGoogle Scholar
  12. 12.
    Declerck PJ, DeMol M, Alessi MC, Bauder S, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988;263:15,454–15,461.Google Scholar
  13. 13.
    Ehrlich HJ, Gebbin KPK, Keijer J, Linders M, et al. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990;265:13,029–13,035.Google Scholar
  14. 14.
    Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987;70:721–728.PubMedGoogle Scholar
  15. 15.
    Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989;264:10,396–10,401.Google Scholar
  16. 16.
    AndreasenPA,GeorgB,LundLR,etal.Plasminogenactivatorinhibitors:hormonallyregulatedserpins. Mol Cell Endocrinol 1990;68:1–19.Google Scholar
  17. 17.
    Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74: 222–228.PubMedGoogle Scholar
  18. 18.
    Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995–1001.PubMedCrossRefGoogle Scholar
  19. 19.
    Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515–2520.PubMedCrossRefGoogle Scholar
  20. 20.
    Cagliero E, Roth T, Roy S, et al. Expression of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem 1991;266:14,244–14,250.Google Scholar
  21. 21.
    Maiello M, Boeri D, Podesta F, Cagliero E, et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992;41:1009–1015.PubMedCrossRefGoogle Scholar
  22. 22.
    Nordt TK, Klassen KJ, Schneider DJ, Sobel BE, et al. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993;13:1822–1828.PubMedCrossRefGoogle Scholar
  23. 23.
    Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994;89:321–330.PubMedCrossRefGoogle Scholar
  24. 24.
    KruithofEK,NicolosaG,BachmannF.Plasminogenactivatorinhibitor1:developmentofaradioimmunoassay and observations on its plasma concentration during venous occlusion and afterplatelet aggregation. Blood 1987;70:1645–1653.Google Scholar
  25. 25.
    Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101–106.PubMedCrossRefGoogle Scholar
  26. 26.
    Kurnik P. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995;91: 1341–1346.PubMedCrossRefGoogle Scholar
  27. 27.
    Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990;16:207–216.PubMedCrossRefGoogle Scholar
  28. 28.
    Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, et al. Deficient tPA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57: 67–72.PubMedGoogle Scholar
  29. 29.
    Hamsten A, Wiman B, deFaire U, Blomback M, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557–1563.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamsten A, deFaire U, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076–1079.PubMedCrossRefGoogle Scholar
  32. 32.
    Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998–7002.PubMedCrossRefGoogle Scholar
  33. 33.
    Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989;1: 974–982.PubMedCrossRefGoogle Scholar
  34. 34.
    Grainger DJ, Kirschenlohr HL, Metcalf JL, Weissberg PL, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655–1658.PubMedCrossRefGoogle Scholar
  35. 35.
    Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes1993;42:1–7.Google Scholar
  36. 36.
    Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, et al. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metab Clin Exp 1993;42:945–949.CrossRefGoogle Scholar
  37. 37.
    Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842–847.PubMedGoogle Scholar
  38. 38.
    Vague P, Juhan-Vague I, Aillaud MF, Badier C, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metab Clin Exp 1986;35:250–253.PubMedCrossRefGoogle Scholar
  39. 39.
    Landin K, Stigendal L, Eriksson E, Krotkiewski M, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metab Clin Exp 1990;39: 1044–1048.PubMedCrossRefGoogle Scholar
  40. 40.
    Juhan-Vague I, Alessi MC, Joly P, Thirion X, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362–367.PubMedCrossRefGoogle Scholar
  41. 41.
    Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients relationship with plasma insulin. Thromb Haemost 1989;61:370–373.PubMedGoogle Scholar
  42. 42.
    Eriksson P, Kallin B, van’t Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851–1855.PubMedCrossRefGoogle Scholar
  43. 43.
    MansfieldMW,SticklandMH,GrantPJ.Plasminogenactivatorinhibitor-1(PAI-1)promoterpolymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1032–1034.Google Scholar
  44. 44.
    Ranby M, Sundell IB, Nilsson TN. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989;62:917–922.PubMedGoogle Scholar
  45. 45.
    Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabete Metab 1991;17:168–173.PubMedGoogle Scholar
  46. 46.
    Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups [see comments]. Diabetes Care 1993;16:621–629.PubMedCrossRefGoogle Scholar
  47. 47.
    Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108–2116.PubMedCrossRefGoogle Scholar
  48. 48.
    Maschio G, Alberti D, Janin G , Locatelli F, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939–945.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Douglas E. Vaughan

There are no affiliations available

Personalised recommendations